Cargando…
Exploring metabolomics biomarkers for evaluating the effectiveness of concurrent radiochemotherapy for cervical cancers
BACKGROUND: Cervical cancer is the second most common female malignancy worldwide. The main method to evaluate the effect of concurrent chemoradiotherapy (CCRT) in the locally advanced stage is imaging which cannot meet the clinical needs. This study aimed to explore potential cervical cancer biomar...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797309/ https://www.ncbi.nlm.nih.gov/pubmed/35117632 http://dx.doi.org/10.21037/tcr.2020.02.49 |
_version_ | 1784641519570911232 |
---|---|
author | Zhou, Huihui Li, Qi Wang, Tong Liang, Hong Wang, Yanan Duan, Yani Song, Min Wang, Yaoxian Jin, Hong |
author_facet | Zhou, Huihui Li, Qi Wang, Tong Liang, Hong Wang, Yanan Duan, Yani Song, Min Wang, Yaoxian Jin, Hong |
author_sort | Zhou, Huihui |
collection | PubMed |
description | BACKGROUND: Cervical cancer is the second most common female malignancy worldwide. The main method to evaluate the effect of concurrent chemoradiotherapy (CCRT) in the locally advanced stage is imaging which cannot meet the clinical needs. This study aimed to explore potential cervical cancer biomarkers via plasma metabolomics and evaluate the effectiveness of CCRT and disease progression. METHODS: Twenty-four primary and thirty recurrent patients were enrolled between November 2016 and November 2017. Plasma samples were obtained by centrifugation of whole blood collected from enrolled patients at admission and from primary patients after CCRT. Plasma metabolic profiles were determined via ultra-performance liquid chromatography with quadrupole time-of-flight mass spectrometry. Multivariate analyses and public databases were used to screen and identify differential metabolites. Pathway analysis was conducted using MetaboAnalyst. RESULTS: Metabolic profiles obtained were significantly different among primary, post-CCRT-treated, and recurrent patients. Multivariate analyses showed that 37 metabolites differed significantly among the three groups, of which the levels of 22 metabolites changed significantly after CCRT and recovered or even exceeded the levels in primary patients when the tumor reappeared. These 22 metabolites were mainly lipids involved in sphingolipid and glycerophospholipid metabolism. Among them, 8 metabolites with area under curve values above 0.75 between each pair of groups exhibited great potential for evaluating CCRT effectiveness and disease progression. CONCLUSIONS: Our results show significantly different plasma metabolic profiles among the three cervical cancer groups; 8 metabolites were identified as potential biomarkers to evaluate the effectiveness of CCRT and disease progression, which can help evaluate the prognosis and treatment of cervical cancer in a timely manner. |
format | Online Article Text |
id | pubmed-8797309 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-87973092022-02-02 Exploring metabolomics biomarkers for evaluating the effectiveness of concurrent radiochemotherapy for cervical cancers Zhou, Huihui Li, Qi Wang, Tong Liang, Hong Wang, Yanan Duan, Yani Song, Min Wang, Yaoxian Jin, Hong Transl Cancer Res Original Article BACKGROUND: Cervical cancer is the second most common female malignancy worldwide. The main method to evaluate the effect of concurrent chemoradiotherapy (CCRT) in the locally advanced stage is imaging which cannot meet the clinical needs. This study aimed to explore potential cervical cancer biomarkers via plasma metabolomics and evaluate the effectiveness of CCRT and disease progression. METHODS: Twenty-four primary and thirty recurrent patients were enrolled between November 2016 and November 2017. Plasma samples were obtained by centrifugation of whole blood collected from enrolled patients at admission and from primary patients after CCRT. Plasma metabolic profiles were determined via ultra-performance liquid chromatography with quadrupole time-of-flight mass spectrometry. Multivariate analyses and public databases were used to screen and identify differential metabolites. Pathway analysis was conducted using MetaboAnalyst. RESULTS: Metabolic profiles obtained were significantly different among primary, post-CCRT-treated, and recurrent patients. Multivariate analyses showed that 37 metabolites differed significantly among the three groups, of which the levels of 22 metabolites changed significantly after CCRT and recovered or even exceeded the levels in primary patients when the tumor reappeared. These 22 metabolites were mainly lipids involved in sphingolipid and glycerophospholipid metabolism. Among them, 8 metabolites with area under curve values above 0.75 between each pair of groups exhibited great potential for evaluating CCRT effectiveness and disease progression. CONCLUSIONS: Our results show significantly different plasma metabolic profiles among the three cervical cancer groups; 8 metabolites were identified as potential biomarkers to evaluate the effectiveness of CCRT and disease progression, which can help evaluate the prognosis and treatment of cervical cancer in a timely manner. AME Publishing Company 2020-04 /pmc/articles/PMC8797309/ /pubmed/35117632 http://dx.doi.org/10.21037/tcr.2020.02.49 Text en 2020 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/. |
spellingShingle | Original Article Zhou, Huihui Li, Qi Wang, Tong Liang, Hong Wang, Yanan Duan, Yani Song, Min Wang, Yaoxian Jin, Hong Exploring metabolomics biomarkers for evaluating the effectiveness of concurrent radiochemotherapy for cervical cancers |
title | Exploring metabolomics biomarkers for evaluating the effectiveness of concurrent radiochemotherapy for cervical cancers |
title_full | Exploring metabolomics biomarkers for evaluating the effectiveness of concurrent radiochemotherapy for cervical cancers |
title_fullStr | Exploring metabolomics biomarkers for evaluating the effectiveness of concurrent radiochemotherapy for cervical cancers |
title_full_unstemmed | Exploring metabolomics biomarkers for evaluating the effectiveness of concurrent radiochemotherapy for cervical cancers |
title_short | Exploring metabolomics biomarkers for evaluating the effectiveness of concurrent radiochemotherapy for cervical cancers |
title_sort | exploring metabolomics biomarkers for evaluating the effectiveness of concurrent radiochemotherapy for cervical cancers |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797309/ https://www.ncbi.nlm.nih.gov/pubmed/35117632 http://dx.doi.org/10.21037/tcr.2020.02.49 |
work_keys_str_mv | AT zhouhuihui exploringmetabolomicsbiomarkersforevaluatingtheeffectivenessofconcurrentradiochemotherapyforcervicalcancers AT liqi exploringmetabolomicsbiomarkersforevaluatingtheeffectivenessofconcurrentradiochemotherapyforcervicalcancers AT wangtong exploringmetabolomicsbiomarkersforevaluatingtheeffectivenessofconcurrentradiochemotherapyforcervicalcancers AT lianghong exploringmetabolomicsbiomarkersforevaluatingtheeffectivenessofconcurrentradiochemotherapyforcervicalcancers AT wangyanan exploringmetabolomicsbiomarkersforevaluatingtheeffectivenessofconcurrentradiochemotherapyforcervicalcancers AT duanyani exploringmetabolomicsbiomarkersforevaluatingtheeffectivenessofconcurrentradiochemotherapyforcervicalcancers AT songmin exploringmetabolomicsbiomarkersforevaluatingtheeffectivenessofconcurrentradiochemotherapyforcervicalcancers AT wangyaoxian exploringmetabolomicsbiomarkersforevaluatingtheeffectivenessofconcurrentradiochemotherapyforcervicalcancers AT jinhong exploringmetabolomicsbiomarkersforevaluatingtheeffectivenessofconcurrentradiochemotherapyforcervicalcancers |